NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

• ClinicalTrials.gov Identifier: NCT02994433
• Recruitment Status: Terminated
• First Posted: December 15, 2016
• Last Update Posted: August 2, 2021
• Sponsor: Washington University School of Medicine
• Information provided by (Responsible Party): Washington University School of Medicine

Study Description

Brief Summary:

Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as treatment-resistant major depression (TRMD). New treatments for TRMD are needed, and one promising line of research are drugs known as N-methyl-D-aspartate (NMDA) glutamate receptor antagonists. In a recent pilot study, our group demonstrated that the NMDA antagonist nitrous oxide is effective in TRMD. This application proposes to take the next important step in understanding how nitrous oxide exerts its effects in the human brain by using state-of-the-art brain neuroimaging (functional connectivity magnetic resonance imaging) in a group of non-depressed, healthy volunteers and comparing the results to a group of TRMD patients.

This study involves exposing 20 non-depressed healthy participants and 20 TRMD participants to nitrous oxide and a placebo gas, to compare their brain images before and after each of the inhalation sessions. Sessions will be separated by at least one month to prevent treatment effects from carrying over into the following session. All willing and eligible subjects will undergo up to six functional connectivity MRI scans, and two inhalation sessions. Functional imaging in the brain will allow us to trace the interconnections between various parts of the brain, including those involved with emotion and depression.

Other procedures will involve screening materials to ensure safety of the participants before beginning the study (i.e. no MRI scan contraindications) and that subjects meet eligibility criteria to being in the targeted age range, depression/non-depressed state, neurological disorder history, and no medication exclusions.

Condition or disease	Intervention/treatment	Phase
Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant	Drug: Nitrous Oxide; Drug: Placebo gas; Device: MRI	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 49 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
• Actual Study Start Date: January 27, 2017
• Actual Primary Completion Date: February 28, 2020
• Actual Study Completion Date: February 28, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Nitrous Oxide; One hour inhalation of nitrous oxide	Drug: Nitrous Oxide; Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.; Other Name: laughing gas; Device: MRI; MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
Placebo Comparator: Placebo Gas; One hour inhalation of placebo gas	Drug: Placebo gas; Placebo gas given at 50% nitrogen [inert]/50% oxygen.; Device: MRI; MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.

Outcome Measures

Primary Outcome Measures :

1. Comparison of functional connectivity between default mode network of treatment-resistant depressed and non-depressed participants [ Time Frame: 2 hours after inhalation ]
   Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.
2. Comparison of functional connectivity between affective network of treatment-resistant depressed and non-depressed participants [ Time Frame: 2 hours after inhalation ]
   Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.
3. Comparison of functional connectivity between cognitive control network of treatment-resistant depressed and non-depressed participants [ Time Frame: 2 hours after inhalation ]
   Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.
4. Comparison of functional connectivity between dorsal nexus of treatment-resistant depressed and non-depressed participants [ Time Frame: 2 hours after inhalation ]
   Functional connectivity is measured between groups after inhaling nitrous oxide/placebo using an individual seed-voxel z map and pared t-test group analysis to identify effects on inter-regional connectivity.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Adults 18-65 years of age
• Right-handed
• Controls: Not meet The Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD) by scoring ≤7 on the Hamilton Depression Rating Scale (HDRS), 17-item; Treatment-Resistant Major Depression (TRMD) patients: Must meet a ≥17 score on the HDRS.
• Controls: Must not have any history of depression as determined by reported history and medical record review; TRMD: Documented (chart review) failure to respond to ≥3-4 adequate dose/duration antidepressant treatments; ≥1 in the current depressive episode.
• Good command of the English language

Exclusion Criteria:

• Meets criteria for any DSM-IV Axis I diagnosis as documented in medical records and as determined by structured clinical interview (except MDD for the TRMD group)
• Known primary neurological disorders or medical disorders including dementia, stroke, encephalopathy Parkinson's Disease, brain tumors, multiple sclerosis, seizure disorder, severe cardiac or pulmonary disease
• Any central nervous system active medication as determined by study investigator
• Any known disease affecting drug metabolism and excretion (e.g. renal or liver disease) as determined by study investigator
• Left-handedness
• Not eligible for MRI scans (e.g. history of claustrophobia/implanted metal as per MRI Screening Tool)
• Current use of psychotropic medications, antidepressants, or prescription or non-prescription drugs/herbals intended to treat depression or anxiety (control group only)
• Any recent (within past 12 months) history of substance dependence or abuse, determined by reported history or urine drug screen
• Ability to become pregnant and not using effective contraception

• Contraindication against the use of nitrous oxide:

  1. Pneumothorax
  2. Bowel obstruction
  3. Middle ear occlusion
  4. Elevated intracranial pressure
  5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12
  6. Pregnant patients
  7. Breastfeeding women
• Inability to provide informed consent
• Any other factor that in the investigators' judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic).

Contacts and Locations

Locations

United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110

Sponsors and Collaborators

Washington University School of Medicine

Investigators

• Principal Investigator: Charles R Conway, MD; Washington University School of Medicine

More Information

• Responsible Party: Washington University School of Medicine
• ClinicalTrials.gov Identifier: NCT02994433
• Other Study ID Numbers: 201606120
• First Posted: December 15, 2016
• Last Update Posted: August 2, 2021
• Last Verified: July 2021

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Depressive Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Mood Disorders; Mental Disorders; Behavioral Symptoms; Nitrous Oxide; Anesthetics, Inhalation; Anesthetics, General; Anesthetics; Central Nervous System Depressants; Physiological Effects of Drugs; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents